金黄色葡萄球菌对莫西沙星的活性及耐药性
Activity of and resistance to moxifloxacin in Staphylococcus aureus.
作者信息
Ince Dilek, Zhang Xiamei, Hooper David C
机构信息
Division of Infectious Diseases and Medical Services, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114-2696, USA.
出版信息
Antimicrob Agents Chemother. 2003 Apr;47(4):1410-5. doi: 10.1128/AAC.47.4.1410-1415.2003.
Abstract
Moxifloxacin has enhanced potency against Staphylococcus aureus, lower propensity to select for resistant mutants, and higher bactericidal activity against highly resistant strains than ciprofloxacin. Despite similar activity against purified S. aureus topoisomerase IV and DNA gyrase, it selects for topoisomerase IV mutants, making topoisomerase IV the preferred target in vivo.
摘要
莫西沙星对金黄色葡萄球菌的抗菌效力增强，筛选耐药突变体的倾向较低，且对高度耐药菌株的杀菌活性高于环丙沙星。尽管对纯化的金黄色葡萄球菌拓扑异构酶IV和DNA旋转酶的活性相似，但它会筛选出拓扑异构酶IV突变体，使拓扑异构酶IV成为体内的首选靶点。
相似文献
1
Activity of and resistance to moxifloxacin in Staphylococcus aureus.金黄色葡萄球菌对莫西沙星的活性及耐药性
Antimicrob Agents Chemother. 2003 Apr;47(4):1410-5. doi: 10.1128/AAC.47.4.1410-1415.2003.
2
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.DNA回旋酶和拓扑异构酶IV的双重靶向作用：新型去氟喹诺酮类药物加替沙星（BMS-284756，T-3811ME）的靶点相互作用
Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002.
3
The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.莫西沙星对来自大肠杆菌和金黄色葡萄球菌的靶标拓扑异构酶的作用。
J Antimicrob Chemother. 1999 May;43 Suppl B:31-7. doi: 10.1093/jac/43.suppl_2.31.
4
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.曲伐沙星与其他氟喹诺酮类药物对金黄色葡萄球菌纯化的拓扑异构酶以及gyrA和grlA突变体的活性比较。
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
5
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.肺炎链球菌中吉米沙星与曲伐沙星、环丙沙星、加替沙星和莫西沙星的单步及多步耐药性选择研究
J Antimicrob Chemother. 2001 Sep;48(3):365-74. doi: 10.1093/jac/48.3.365.
6
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.双重靶向拓扑异构酶IV和回旋酶以减少突变选择：使用新型氟喹诺酮类药物WCK-1734和环丙沙星对该范例进行直接测试。
Antimicrob Agents Chemother. 2005 May;49(5):1949-56. doi: 10.1128/AAC.49.5.1949-1956.2005.
7
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.金黄色葡萄球菌和肺炎链球菌对不同氟喹诺酮类药物的耐药性选择及致突变性
Clin Microbiol Infect. 2005 Sep;11(9):750-8. doi: 10.1111/j.1469-0691.2005.01211.x.
8
Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.吉米沙星和其他氟喹诺酮介导的野生型和耐喹诺酮肺炎链球菌II型拓扑异构酶形成可裂解复合物
Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. doi: 10.1128/AAC.46.2.413-419.2002.
9
Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.新型氟萘啶酮抗生素DW286对DNA旋转酶和拓扑异构酶IV发生特定突变的金黄色葡萄球菌菌株的抗菌活性增强。
Int J Antimicrob Agents. 2005 Apr;25(4):334-7. doi: 10.1016/j.ijantimicag.2004.11.013.
10
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.新型去氟（6）喹诺酮类药物BMS-284756对金黄色葡萄球菌的活性，包括喹诺酮耐药性突变的作用。
Antimicrob Agents Chemother. 2002 Apr;46(4):1119-21. doi: 10.1128/AAC.46.4.1119-1121.2002.
引用本文的文献
1
Prediction of microbe-drug associations using a CNN-Bernoulli random forest model.使用卷积神经网络-伯努利随机森林模型预测微生物-药物关联
PeerJ. 2025 Aug 5;13:e19637. doi: 10.7717/peerj.19637. eCollection 2025.
2
Post-fluoroquinolone treatment molecular events and nutrient availability modulate antibiotic persistence.氟喹诺酮治疗后的分子事件和营养物质可用性调节抗生素持续性。
bioRxiv. 2025 Jun 26:2025.06.26.661800. doi: 10.1101/2025.06.26.661800.
3
Dynamic category-sensitive hypergraph inferring and homo-heterogeneous neighbor feature learning for drug-related microbe prediction.动态类别敏感超图推断与同异质邻居特征学习在药物相关微生物预测中的应用。
Bioinformatics. 2024 Sep 2;40(9). doi: 10.1093/bioinformatics/btae562.
4
Efflux pump inhibitory potential of indole derivatives as an arsenal against over-expressing .吲哚衍生物作为对抗过度表达的一种手段的外排泵抑制潜力
Microbiol Spectr. 2023 Sep 27;11(5):e0487622. doi: 10.1128/spectrum.04876-22.
5
Efficacy of antibiotic treatment of implant-associated infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study.莫西沙星、氟氯西林、利福平及联合治疗对种植体相关感染的抗生素治疗效果：一项动物研究。
Drug Des Devel Ther. 2017 Jun 14;11:1729-1736. doi: 10.2147/DDDT.S138888. eCollection 2017.
6
De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.体外针对抗结核药物形成的持留期细胞中结核分枝杆菌遗传抗性突变体的从头出现。
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01343-16. Print 2017 Feb.
7
Profile of microbial keratitis after corneal collagen cross-linking.角膜胶原交联术后微生物性角膜炎概况
Biomed Res Int. 2014;2014:340509. doi: 10.1155/2014/340509. Epub 2014 Sep 11.
8
Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea.韩国金黄色葡萄球菌临床分离株中norB过表达与氟喹诺酮耐药性的关联
J Antimicrob Chemother. 2013 Dec;68(12):2766-72. doi: 10.1093/jac/dkt286. Epub 2013 Aug 8.
9
Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.ACH-702 对非分裂和生物膜葡萄球菌的杀菌活性。
Antimicrob Agents Chemother. 2012 Jul;56(7):3812-8. doi: 10.1128/AAC.00092-12. Epub 2012 Apr 30.
10
In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.ACH-702 作为一种异噻唑酮喹诺酮类药物，其针对细菌病原体的体外和体内特性。
Antimicrob Agents Chemother. 2011 Jun;55(6):2860-71. doi: 10.1128/AAC.01666-10. Epub 2011 Apr 4.
本文引用的文献
1
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.DNA回旋酶和拓扑异构酶IV的双重靶向作用：新型去氟喹诺酮类药物加替沙星（BMS-284756，T-3811ME）的靶点相互作用
Antimicrob Agents Chemother. 2002 Nov;46(11):3370-80. doi: 10.1128/AAC.46.11.3370-3380.2002.
2
Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.与肺炎链球菌体外筛选对莫西沙星耐药性相关的拓扑异构酶突变
Antimicrob Agents Chemother. 2002 Aug;46(8):2712-5. doi: 10.1128/AAC.46.8.2712-2715.2002.
3
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.对莫西沙星和左氧氟沙星敏感性降低的肺炎链球菌突变体的筛选。
Antimicrob Agents Chemother. 2002 Feb;46(2):522-4. doi: 10.1128/AAC.46.2.522-524.2002.
4
Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.吉米沙星和其他氟喹诺酮介导的野生型和耐喹诺酮肺炎链球菌II型拓扑异构酶形成可裂解复合物
Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. doi: 10.1128/AAC.46.2.413-419.2002.
5
Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.基于抗菌活性和靶点抑制作用，15种喹诺酮类药物对金黄色葡萄球菌的靶点偏好性
Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. doi: 10.1128/AAC.45.12.3544-3547.2001.
6
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.莫西沙星、环丙沙星和万古霉素对表达不同程度环丙沙星耐药性的耐甲氧西林金黄色葡萄球菌所致实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2001 Nov;45(11):3076-83. doi: 10.1128/AAC.45.11.3076-3083.2001.
7
Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.金黄色葡萄球菌中加替沙星与AM-1121及环丙沙星相比的耐药机制和耐药频率
Antimicrob Agents Chemother. 2001 Oct;45(10):2755-64. doi: 10.1128/AAC.45.10.2755-2764.2001.
8
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.金黄色葡萄球菌对普马沙星的耐药机制及频率：新突变提示新的药物-靶点相互作用
Antimicrob Agents Chemother. 2000 Dec;44(12):3344-50. doi: 10.1128/AAC.44.12.3344-3350.2000.
9
Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.作为氟喹诺酮对分枝杆菌效力衡量指标的突变预防浓度
Antimicrob Agents Chemother. 2000 Dec;44(12):3337-43. doi: 10.1128/AAC.44.12.3337-3343.2000.
10
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.莫西沙星的细胞内靶点：与其他氟喹诺酮类药物的比较。
J Antimicrob Chemother. 2000 May;45(5):583-90. doi: 10.1093/jac/45.5.583.
Zotero 插件